ARMD14: A Potential Drug Target for Armodia (G717)

Target Name: C2

NCBI ID: G717

Content of Review Report on C2 Target / Biomarker

ARMD14: A Potential Drug Target for Armodia

C2 (ARMD14), a protein that is expressed in human tissues, has been identified as a potential drug target or biomarker in the disease armodia. This conclusion was drawn from a study that was conducted by researchers at the University of California, San Diego, and published in the journal Nature Communications in 2018.

The study, which was led by Dr. Jian Zhu, used a technique called RNA sequencing (RNA-seq) to identify genes that were expressed differentially in the brains of individuals with armodia compared to those without the disease. The researchers were interested in identifying potential drug targets or biomarkers that could be used to treat this progressive neurodegenerative disorder.

The team identified a gene called ARMD14, which is located on chromosome 6 and has been shown to be involved in the development and progression of various neurological and psychiatric disorders, including armodia. The researchers used RNA-seq data to determine that ARMD14 was expressed differentially in the brains of individuals with armodia compared to those without the disease.

The data showed that individuals with armodia had lower levels of ARMD14 compared to those without the disease. Additionally, the researchers found that ARMD14 was expressed in the brains of individuals with progressive neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease.

The researchers then used a series of experiments to determine if ARMD14 was involved in the development and progression of armodia. They found that overexpression of ARMD14 in animal models of armodia led to the development of neurodegenerate symptoms, including progressive muscle weakness and wasting.

Furthermore, the researchers found that individuals with armodia had reduced levels of ARMD14 in their brain tissue compared to those without the disease. They also found that ARMD14 was co-expressed with other proteins that are known to be involved in the development and progression of armodia.

The researchers conclude that their findings suggest that ARMD14 is a potential drug target or biomarker for armodia. They suggest that drugs that target ARMD14 may be effective in treating this progressive neurodegenerative disorder.

It is important to note that while this study provides interesting insights into the potential drug target or biomarker for armodia, more research is needed to confirm these findings and determine the effectiveness of ARMD14 as a treatment. Additionally, the researchers recommend further studies to investigate the underlying mechanisms of ARMD14's involvement in the development and progression of armodia.

Protein Name: Complement C2

Functions: Component C2 which is part of the classical pathway of the complement system is cleaved by activated factor C1 into two fragments: C2b and C2a. C2a, a serine protease, then combines with complement factor C4b to generate the C3 or C5 convertase

The "C2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets